| Literature DB >> 29988450 |
Angel Pulido-Capiz1, Raúl Díaz-Molina1, Israel Martínez-Navarro1,2, Lizbeth A Guevara-Olaya1, Enrique Casanueva-Pérez1, Jaime Mas-Oliva3, Ignacio A Rivero4, Victor García-González1.
Abstract
The islet amyloid polyEntities:
Keywords: IAPP; amyloids; biomimetics; cholesterol; diabetes mellitus type 2; hepatocytes; insulin; metabolism
Year: 2018 PMID: 29988450 PMCID: PMC6026639 DOI: 10.3389/fendo.2018.00331
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Figure 1Analysis of primary structure of islet amyloid polypeptide (IAPP) among 240 species. (A) Evaluation of multiple alignments of 240 sequences showing the conserved sites (24). (B) Analysis of correlation among Aggrescan and hydropathy values of sequences. (C) Distribution of Aggrescan values throughout 240 sequences of IAPP. Negative values were associated with lower aggregation propensity, and positive values with higher aggregation propensity. In black line is identified the sequence of hIAPP.
Primary structure of hIAPP placed in order position, showing the different variants that were originated from the comparison among 240 sequences, the frequency of each variant is shown.
| Position | Amino acid | Variants | Residue variants | Total of sequences with the specific variants | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | K | K1R | K1E | K1I | 3 | 10 | |||||
| 2 | C | 0 | 0 | ||||||||
| 3 | N | N3G | N3D | 2 | 15 | ||||||
| 4 | T | T4I | T4M | 2 | 6 | ||||||
| 5 | A | A5V | A5I | A5P | 3 | 7 | |||||
| 6 | T | T6I | 1 | 1 | |||||||
| 7 | C | C7Y | 1 | 1 | |||||||
| 8 | A | A8V | A8S | A8E | A8T | 4 | 168 | ||||
| 9 | T | T9M | T9I | 2 | 12 | ||||||
| 10 | Q | Q10H | 1 | 5 | |||||||
| 11 | R | R11E | R11W | R11H | 3 | 5 | |||||
| 12 | L | 0 | 0 | ||||||||
| 13 | A | A13T | A13V | A13S | 3 | 16 | |||||
| 14 | N | N14D | N14T | N14H | 3 | 153 | |||||
| 15 | F | F15Y | 1 | 1 | |||||||
| 16 | L | 0 | 0 | ||||||||
| 17 | V | V17D | V17G | V17T | V17A | V17I | V17S | 6 | 34 | ||
| 18 | H | H18R | 1 | 209 | |||||||
| 19 | S | S19T | S19F | S19A | 3 | 4 | |||||
| 20 | S | S20G | S20N | S20C | S20R | 4 | 28 | ||||
| 21 | N | N21S | N21G | N21H | 3 | 43 | |||||
| 22 | N | N22S | N22T | N22I | N22K | N22G | 5 | 66 | |||
| 23 | F | F23I | F23L | F23M | F23R | F23A | F23V | F23G | 7 | 206 | |
| 24 | G | G24R | G24A | G24S | 3 | 4 | |||||
| 25 | A | A25T | A25D | A25P | A25V | A25S | A25I | 6 | 52 | ||
| 26 | I | I26V | I26A | I26L | I26M | I26Y | 5 | 74 | |||
| 27 | L | L27Y | L27I | L27F | L27S | L27H | L27X | 6 | 166 | ||
| 28 | S | S28V | S28A | S28L | S28P | S28T | 5 | 53 | |||
| 29 | S | S29P | S29A | S29T | S29H | S29L | 5 | 211 | |||
| 30 | T | T30V | T30P | T30R | T30N | 4 | 5 | ||||
| 31 | N | N31K | N31D | N31S | N31V | 4 | 32 | ||||
| 32 | V | V32M | V32L | V32G | 3 | 10 | |||||
| 33 | G | G33S | 1 | 1 | |||||||
| 34 | S | S34A | S34P | 2 | 4 | ||||||
| 35 | N | N35S | N35A | N35T | N35Y | N35D | N35G | N35H | N35K | 8 | 30 |
| 36 | T | T36A | T36S | 2 | 5 | ||||||
| 37 | Y | Y37H | 1 | 3 | |||||||
The amino acids of the hIAPP sequence are shown in gray shades.
Figure 2Single modifications on hIAPP could originate 113 de novo sequences that modulate the amyloid aggregation in islet amyloid polypeptide. (A) Effect of residue substitution on the hIAPP (residues 1–37), showed by the Aggrescan values. Orange variants in regions 17–31 are identified; black bar corresponds to hIAPP. (B) Association of hydropathy and Aggrescan values of 113 de novo variants. (C) Sigmoidal trend was registered in aggregation values of 113 de novo variants. (D) Sequences of species with low aggregation tendency in contrast to less aggregative sequences de novo with two substitutions. hIAPP was used as a reference, in red, were identified the variants.
Effect of substitutions of individual variants on human amylin sequence.
| Variant | Sequence | Na4VSS | Hidroph. | PASTA | Organisms |
|---|---|---|---|---|---|
| V17D | −14.8 | −0.31 | −3.46 | ||
| F23R | −13.6 | −0.30 | −3.88 | ||
| L27H | −12.1 | −0.29 | −4.10 | ||
| F23G | −11.7 | −0.18 | −3.88 | ||
| V32G | −11.3 | −0.22 | −4.21 | ||
| V17G | −11.3 | −0.22 | −3.46 | ||
| I26A | −10.6 | −0.17 | −3.88 | ||
| A25D | −10.4 | −0.24 | −3.95 | ||
| F23A | −10.4 | −0.12 | −3.88 | ||
| V17T | −10.3 | −0.23 | −3.46 | ||
| L27S | −10.1 | −0.22 | −6.19 | ||
| V17A | −10.0 | −0.16 | −3.46 | ||
| A8E | −9.3 | −0.24 | −4.94 | ||
| Y37H | −9.1 | −0.15 | −4.94 | ||
| T36S | −9.1 | −0.10 | −4.94 | ||
| −5.6 | − | −4.94 | |||
| K1I | −1.1 | 0.13 | −4.94 | ||
| S29L | −1.0 | 0.03 | −6.36 | ||
| S28L | −1.0 | 0.03 | −6.36 | ||
| T30V | −0.8 | 0.04 | −6.86 | ||
| S28V | −0.5 | 0.04 | −7.61 | ||
| A25I | −0.5 | −0.02 | −7.41 | ||
| A5I | −0.5 | −0.02 | −4.94 | ||
| T9I | −0.2 | 0.04 | −4.94 | ||
| T6I | −0.2 | 0.04 | −4.94 | ||
| S19F | 0.0 | 0.00 | −6.50 | ||
| R11W | 0.6 | 0.00 | −5.84 | ||
| T4I | 0.9 | 0.04 | −4.94 | ||
| N35Y | 1.1 | −0.04 | −4.94 | ||
| N31V | 2.3 | 0.11 | −6.97 | ||
| N22I | 2.9 | 0.12 | −3.46 |
In order, 15 sequences with lower aggregation and 15 with greater aggregation are showed, compared to hIAPP. Hot spots regions are identified in red.
Hidroph., hydrophobicity in kilocalorie per mole.
Figure 3The F23R variant modulates beta-sheet formation in C-terminal 23–37 islet amyloid polypeptide domain. (A) Emission values obtained with ThT-fluorescence assay, the peak was recorded at 482 nm. (B) Circular dichroism spectra of the variants. (C) Cell viability evaluated through MTT assay in RIN-m5F cells under increasing concentrations of peptides. Mean values were presented (n = 6, X ± SD) *p < 0.001, **p < 0.005. Peptide samples processed by transmission electron microscopy of C-terminal (D,F,H) and F23R variant (E,G,I). Bars correspond to 500 nm.
Figure 4Effect of phosphatidylcholine (PC) vesicles on secondary structural changes in peptides derived from islet amyloid polypeptide. (A) Fluorescence values at 482 nm in the native C-terminal incubated with PC vesicles. (B) Under the same conditions, the emission spectra were shown. (C) Fluorescence values in the F23R variant incubated with increasing concentrations of PC. (D) Under the same conditions, the emission spectra were obtained.
Figure 5F23R inhibits conformational changes toward the formation of beta-structures in the C-terminal of islet amyloid polypeptide. (A) Evaluation of peptide-bond conformational changes in the native C-terminal and F23R in increasing phosphatidylcholine (PC) concentrations. (B) Under the same conditions, values of birefringence change by Congo-red assay. (C) Effect of treatment with PC on the kinetics of aggregation. Characterization of lipid/peptide interactions by native polyacrylamide gradient gels (1–15%) and processed by silver (D) and Sudan black (E) staining.
Figure 6Modulation of amyloid aggregation in the native C-terminal dependent of treatment with F23R. (A) Characterization of beta-sheet structures by Congo-red birefringence assay under equimolar concentrations of peptides. (B) Beta-cell viability assay by MTT at peptide concentrations of 7.5 µg/mL. (C) Insulin quantification in extracellular media under the same conditions. Mean values are presented (n = 6, X ± SD) *p < 0.001, **p < 0.005. (D) Expression of CHOP and ATF6α transcription factors, as well as PMCA and ABCA1 in islet amyloid polypeptide peptide treatments. In this experiment, several controls were evaluated, effect of PA incubation on the expression of CHOP and ATF6α at 4 and 12 h. Under the same concentration (300 µM), oleic acid effect was evaluated on CHOP expression. β-actin was used as a load control. (E) Quantification of PMCA expression compared to control, #p < 0.01.
Figure 7Functional modulation of islet amyloid polypeptide sequences in microglia. (A) Responses of cytotoxicity obtained in the microglia model, using the peptide Aβ as a reference (n = 6, X ± SD) *p < 0.001, **p < 0.05. (B) Under the same treatments, CHOP and IL-6 were evaluated, (C) quantification of CHOP expression compared to β-actin control.
Figure 8Islet amyloid polypeptide (IAPP) sequences modulate cholesterol metabolism in hepatocytes. (A) Cells were treated with equimolar concentrations of peptide variants (7.5 µg/mL), and MTT assay was performed, (B) as well as CHOP, IL-6 and ATF6α expression were evaluated. (C) LPS incubation was used as a positive control of CHOP and IL-6 activation. In addition, fatty acids PA and oleic acid were employed as a regulator condition of CHOP expression. (D) Proteins targets that regulate cholesterol metabolism were characterized, under IAPP peptide incubation. (E) Quantification of ABCA1 expression compared to β-actin control. (F) Cytometer analysis on internalization of dil-LDL (3 µg/mL). (G) Expression of LDLR under hepatocyte stimulation with native dil-LDL. (H) Western-blot of PMCA, and (I) quantification of PMCA expression compared to β-actin control. For western-blot analysis, *p < 0.05, **p < 0.01 compared to control.